Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

The effect of perioperative inhaled iloprost on congenital heart disease with severe pulmonary arterial hypertension

심한 폐동맥 고혈압을 동반한 선천성 심장병 환자에서 수술 전후 Iloprost 효과

  • Kim, Su Nam (Department of Pediatrics, Gil Hospital, Gachon University of Medicine) ;
  • Choi, Deok Young (Department of Pediatrics, Gil Hospital, Gachon University of Medicine)
  • 김수남 (가천의과학대학교 길병원 소아과학교실) ;
  • 최덕영 (가천의과학대학교 길병원 소아과학교실)
  • Received : 2009.09.09
  • Accepted : 2009.10.27
  • Published : 2010.01.15
Download PDF
⟨ Previous Next ⟩

Abstract

A 47-year-old male patient in whom atrial septal defect (ASD) had been diagnosed 15 years previously was admitted for cardiac catheterization. He had definite cyanotic lips and nail beds and severe pulmonary arterial hypertension (PAH). He had received medical treatment only for the last few years after being diagnosed with Eisenmenger syndrome. After cardiac catheterization, he received iloprost inhalation therapy pre and postoperation and was discharged after successful surgical closure of the ASD.

15년전 심방중격 결손증 진단을 받은 47세 남자 환자가 심도자 검사를 위해 입원하였다. 환자는 입술과 손톱에서 명확한 청색증을 보이고 있었으며 심한 폐동맥 고혈압을 나타내고 있었다. 본 환자는 지난 수년간 아이젠멩거 증후군으로 진단되어 대증적 치료만을 받아오고 있었다. 심도자 검사 후 환자는 흡입형 Iloprost 치료를 시작 하였으며 성공적으로 심방중격결손증 수술을 받을 수 있었다. 환자는 수술 후에도 치료를 지속하였다.

Keywords

References

  1. Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 2004;102:139-53 https://doi.org/10.1016/j.pharmthera.2004.01.003
  2. Goldsmith DR, Wagstaff AJ. Inhaled iloprost: in primary pulmonary hypertension. Drugs 2004;64:763-73 https://doi.org/10.2165/00003495-200464070-00009
  3. Engelfriet P, Meijboom F, Boersma E, Tijssen J, Mulder B. Repaired and open atrial septal defects type II in adulthood: An epidemiological study of a large European cohort. Int J Cardiol 2008;126:379-85 https://doi.org/10.1016/j.ijcard.2007.04.044
  4. Engelfriet PM, Duffels MG, Moller T, Boersma E, Tijssen JG, Thaulow E, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart 2007;93:682-7 https://doi.org/10.1136/hrt.2006.098848
  5. Chang WH, Oh TY, Bae SI. Surgical Treatment of Atrial Septal Defect in adult. Korean J Thorac Cardiovasc Surg 1998;31:770-5
  6. Roques F, Nashef P, Michel E. Risk factors and outcome in European cardiac surgery: Analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999;15:816-23 https://doi.org/10.1016/S1010-7940(99)00106-2
  7. Lee JE, Hillier SC, Knoderer CA. Use of sildenafil to facilitate weaning from inhaled nitric oxide in chilren with pulmonary hypertension following surgery for congenital heart disease. J Intensive Care Med 2008;23:329-34 https://doi.org/10.1177/0885066608321389
  8. Kim KB, Choi JS. Treatment of pulmonary hypertensive crisis using ECMO. Korean J Thorac Cardiovasc Surg 2002;35:664-7
  9. Kim JH, Lee KC, Chang YJ, Lim YT, Park JC, Cho YL. Inhaled nitric oxide as a therapy for pulmonary hypertension after operation for congenital heart disease. Korean J Anesthesiol 1999;37:1084-8
  10. Bratel T, Laqerstrand L, Brodin LA, Nowak J, Randmaa I. Ventilation/perfusion ratios in pulmonary arterial hypertension: effects of IV and inhaled prostacyclin derivatives. Chest 2005;128:615S-6S
  11. Hoetzenecker K, Ankersmit HJ, Bonderman D, Hoetzenecker W, Seitelberger R, Klepetko W, et al. Atrial septal defect repair after a 10-month treatment with bosentan in a patient with severe pulmonary arterial hypertension: A case report. J Thorac Cardiovasc Surg 2009;137:760-1 https://doi.org/10.1016/j.jtcvs.2008.03.064
  12. Frost AE, Quinones MA, Zoghbi WA, Noon GP. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant 2005;24:501-3 https://doi.org/10.1016/j.healun.2004.02.004
  13. Schwerzmann M, Zafar M, McLaughlin PR, Chamberlain DW, Webb G, Granton J. Atrial septal defect closure in a patient with 'irreversible' pulmonary hypertensive arteriopathy. Int J Cardiol 2006;110:104-7 https://doi.org/10.1016/j.ijcard.2005.05.062
  14. Kim DK, Kim HK, Lim JA, Jeong SM, Jang SW, Yun IJ. Perioperative combined use of sildenafil and inhaled iloprost for moderate portopulmonary hypertension in a petient undergoing liver trasplantation - A case report-. Korean J Anesthesiol 2008;54:102-8 https://doi.org/10.4097/kjae.2008.54.1.102
  15. Winterhalter M, Simon A, Fischer S, Rahe-Meyer N, Chamtzidou N, Hecker H, et al. Comparison of inhaled iloprost and nitric oxide in patents with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. J Cardiothorac Vasc Anesth 2008;22:406-13 https://doi.org/10.1053/j.jvca.2007.10.015
  16. Jung JW. Pulmonary arterial hypertension of congenital heart disease: from reversible pulmonary hypertension to Eisenmenger syndrome. Korean Circ J 2007;37:287-97 https://doi.org/10.4070/kcj.2007.37.7.287
  17. Viswanathan S, Kumar RK. Assessment of operability of congenital cardiac shunts with increased pulmonary vascular resistance. Catheter Cardiovasc Interv 2008;71:665-70 https://doi.org/10.1002/ccd.21446